HK inno.N Corporation
Clinical trials sponsored by HK inno.N Corporation, explained in plain language.
A pharmaceutical company developing and commercializing drugs and healthcare products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection aims to shed pounds in major obesity trial Results expected Dec 2026 (estimated)
- New GERD drug tegoprazan tested in large real-world study Results expected Jun 2027 (estimated)
- New diabetes shot aims to lower blood sugar in patients not helped by diet alone Results expected Aug 2027 (estimated)
-
New GERD drug tegoprazan tested in large real-world study
Disease control Recruiting nowThis study investigates the safety and symptom-relieving effects of the drug Tegoprazan (K-CAB) in adults with gastroesophageal reflux disease (GERD). Researchers will track how well the drug reduces heartburn and acid reflux after 4 weeks of use. The study includes over 5,000 pa…
Sponsor: HK inno.N Corporation • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New ointment put to the test against eczema
Symptom relief Recruiting nowResearchers are testing an experimental ointment called IN-115314 in adults with mild to moderate atopic dermatitis, a common form of eczema. The trial compares two strengths of the ointment, 1% and 3%, against a placebo ointment. Participants apply the treatment twice daily for …
Phase 2 • Sponsor: HK inno.N Corporation • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC